Bronchodilator Drugs - Haiti | Statista Market Forecast

The Bronchodilator Drugs market in Haiti is forecasted to achieve a revenue of US$3.22m by the year 2024.
It is anticipated to experience a steady annual growth rate (CAGR 2024-2029) of 3.40%, leading to a market volume of US$3.81m by 2029.
Among all countries, United States is expected to generate the highest revenue in this market, reaching US$17.34bn in 2024.
In Haiti, the demand for bronchodilator drugs has significantly increased due to the high prevalence of respiratory diseases in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are widely used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Haiti, the market for bronchodilator drugs is developing in a certain way due to several factors.

Customer preferences: Customers in Haiti prefer affordable and accessible medications. They are price-sensitive and tend to choose generic drugs over branded ones. This is because generic drugs are cheaper and more widely available. In addition, customers prefer inhalers over nebulizers due to their convenience and ease of use.

Trends in the market: The market for bronchodilator drugs in Haiti is growing due to the increasing prevalence of respiratory diseases in the country. This is due to several factors such as air pollution, smoking, and poor living conditions. As a result, there is a higher demand for bronchodilator drugs in the country. In addition, there is a growing trend towards the use of combination bronchodilator drugs, which are more effective in treating respiratory diseases.

Local special circumstances: Haiti is a low-income country with a high burden of disease. The healthcare system in the country is underdeveloped, and access to healthcare is limited. This has resulted in a high prevalence of respiratory diseases, which has led to an increased demand for bronchodilator drugs. However, the availability of these drugs is limited, and many people in the country do not have access to them.

Underlying macroeconomic factors: Haiti is one of the poorest countries in the world, with a low GDP per capita and high levels of poverty. The healthcare system in the country is underfunded and underdeveloped, which has resulted in a lack of access to healthcare for many people. In addition, the country has a high burden of disease, which has put a strain on the healthcare system. These underlying macroeconomic factors have contributed to the development of the bronchodilator drugs market in Haiti.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.